Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Respiratory Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1663773

This article is part of the Research TopicResearch and Innovation Approaches to Personalized Pharmacotherapies for Respiratory DiseasesView all 6 articles

Association Between Acetaminophen Use and 30-Day Mortality in Critically Ill Patients with Pulmonary Embolism: A Retrospective Cohort Study Using the MIMIC-IV Database

Provisionally accepted
Liman  QiuLiman Qiu1Xiankun  LinXiankun Lin2Xunwei  TuXunwei Tu2Linqian  JiangLinqian Jiang2Xiuling  ShangXiuling Shang2Xincai  WangXincai Wang2*Long  HuangLong Huang2*
  • 1Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China
  • 2Fujian Provincial Hospital, Fuzhou, China

The final, formatted version of the article will be published soon.

Purpose: Pulmonary embolism (PE) has high mortality rates among critically ill patients. While acetaminophen shows potential therapeutic effects in critical illness, its impact on ICU patients with PE remains unclear. This study evaluated the association between acetaminophen use and 30-day mortality in ICU patients with PE. Patients and methods: A retrospective cohort study was conducted using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Adult patients admitted to the ICU with confirmed PE between 2008 and 2022 were included. The primary exposure was acetaminophen use during the ICU stay, and the primary outcome was 30-day all-cause mortality. To control for confounding factors, propensity score matching (PSM) was applied, along with inverse probability weighting, propensity score adjustment, and E-value analysis to assess result robustness. Causal mediation analysis was performed to evaluate the mediating role of body temperature. Results: Among 1,983 eligible patients, 1,355 received acetaminophen and 628 did not. After propensity score matching (599 pairs), acetaminophen use was associated with a 31% reduction in 30-day mortality risk (HR 0.69, 95% CI: 0.56–0.85, P=0.001). This protective effect was more pronounced in patients requiring mechanical ventilation (HR 0.53, 95% CI: 0.34–0.82) and vasopressor support (HR 0.52, 95% CI: 0.32–0.83). Enhanced benefits were also observed in younger patients (<65 years, HR 0.52, 95% CI: 0.31–0.85). Multiple sensitivity analyses yielded consistent results, with E-values ranging from 2.03 to 2.26, suggesting robust resistance to unmeasured confounding. Causal mediation analysis revealed that 54.2% (95% CI: 25.6% to 187.5%, P=0.014) of acetaminophen's apparent protective effect was mediated through body temperature regulation during hospitalization. Conclusion: Acetaminophen use was associated with reduced 30-day mortality in critically ill patients with PE, with temperature control appearing to play a potential mediating role. These preliminary findings provide hypothesis-generating evidence that warrants validation in prospective randomized controlled trials before clinical implementation.

Keywords: Acetaminophen, Pulmonary Embolism, Intensive Care Unit, 30-day mortality, Propensity score matching, Causal mediation analysis

Received: 10 Jul 2025; Accepted: 12 Aug 2025.

Copyright: © 2025 Qiu, Lin, Tu, Jiang, Shang, Wang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Xincai Wang, Fujian Provincial Hospital, Fuzhou, China
Long Huang, Fujian Provincial Hospital, Fuzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.